Patients with Breast, Colorectal, and Pancreatic Cancers With ATM, CHEK2, or PALB2 PVs Have Similar Mortality to the Average Genetically Tested Patients By Ogkologos - March 18, 2025 389 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from a population-based study Source RELATED ARTICLESMORE FROM AUTHOR FDA Approves Gemcitabine Intravesical System for Non-Muscle Invasive Bladder Cancer ESMO Calls for Robust EU Taxation of Tobacco Products, Aiming to Prevent Cancers Attributable to Tobacco Use EMA Recommends Granting a Marketing Authorisation for Biosimilar Pegfilgrastim MOST POPULAR A urine test for bladder cancer: What’s the latest? April 16, 2022 Acalabrutinib-Venetoclax With or Without Obinutuzumab Significantly Prolongs PFS in Fit Patients... February 25, 2025 Immunotherapy for Breast Cancer Treatment: Is It an Option? September 21, 2020 Proof of Concept for the Safety and Immunogenicity of Lymph Node... January 18, 2024 Load more HOT NEWS EMA Recommends Granting a Marketing Authorisation for Pomalidomide Viatris Boy Shaves Head To Support Friend Going Through Cancer Cancer in My Community: Addressing Health Disparities in Brazil Neoadjuvant Chemoimmunotherapy Superior to Neoadjuvant Chemotherapy with Event-Free Survival Benefit in...
